Tieneptine sodium powder
Product introduction£º
CAS: 30123-17-2
Appearance: White to yellowish powder
Purity: ¡Ý99%
Solubility: freely soluble In water and methanol and dichloromethane
Any impurity: ¡Ü0.1%
Total impurities: ¡Ü0.4%
Overview: Tieneptine sodium powder also named tianeptine sodium, is is a prescription drug for depression in some European, Asian, and Latin American countries. Tianeptine is most commonly used for depression. It is also used for pain, asthma, anxiety, and other conditions.
Associated Conditions: Major Depressive Disorder (MDD)
Application: Prescription tianeptine sodium powder is used to reduce depressive symptoms in people with depression. It might work as well as certain other medicines commonly used for depression.
Dosage: Adults, 25 or 37.5 mg of tianeptine daily has been used as a prescription drug under the guidance of a health care professional.
Other chemical names: Tianeptine sodium salt, S-1574, Stablon, Coaxil sodiuM salt, Tieneptine sodium salt hydrate,
7-[(3-Chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic Acid S,S-Dioxide Sodium Salt
Certificate of analysia
Product
|
Tieneptine sodium powder
|
batch No.
|
202005001
|
Mfg. date
|
20200506
|
CAS No.
|
30123-17-2
|
Exp. date
|
20220505
|
Tests
|
Results
|
Specifications
|
Description
|
Off-white powder,very hygroscopic.
|
White to yellowish powder,very hygroscopic.
|
Solubility
|
Complies
|
Freetly soluble In water and methanol and dichloromethane
|
Identification
|
Complies
|
£¨1£©By IR, To match with working standard
|
Complies
|
£¨2£©It gives reaction of sodium
|
Impurities A
|
Not detected
|
¡Ü0.1%
|
Related compounds
|
£¼0.1%
|
Any impurity ¡Ü0.1%
|
0.19%
|
Total impurities ¡Ü0.4%
|
Residual
Solvents
|
Not detected
|
Acetidin¡Ü 0.5%
|
0.04%
|
Dichloromethane¡Ü 0.06%
|
0.01%
|
Methanol¡Ü 0.3%
|
0.01%
|
Acetone ¡Ü 0.5%
|
Not detected
|
Acetonitrile¡Ü0.041%
|
0.01%
|
Ethanol¡Ü0.5%
|
Not detected
|
N, N-dimethylformamide ¡Ü0.088%
|
Water
|
2.35%
|
¡Ü 5.0%
|
Assay
|
99.35%
|
99.0%-101.0%£¨On anhydrous basis£©
|
Conclusion£º Conform to EP8.0
|